Bio-Rad Labs misses Q3 estimates for profit, revenue

seekingalpha

01 Nov 2024

Bio-Rad Labs press release (NYSE:BIO): Q3 Non-GAAP EPS of $2.01 misses by $0.87.
Revenue of $649.7M (+2.8% Y/Y) misses by $32.45M.
Bio-Rad continues to expect its non-GAAP revenue to decline by approximately 2.5% to 4% on a currency-neutral basis.
The company estimates a non-GAAP operating margin of between 12.75% to 13.25%, which now also includes the impact of a one-time acquired in-process research and development expense related to an acquisition completed during the third quarter.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2480079950"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2480079950\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2480079950?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-01 14:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480079950","market":"us","top_or_hot":-1,"title":"Bio-Rad Labs misses Q3 estimates for profit, revenue","media":"seekingalpha","content":"<html><body><ul> <li>Bio-Rad Labs press release  (<span>NYSE:BIO</span>): Q3 Non-GAAP EPS of $2.01 <span> misses by $0.87</span>.</li> <li>Revenue of $649.7M (+2.8% Y/Y) <span> misses by $32.45M</span>.</li> <li>Bio-Rad continues to expect its non-GAAP revenue to decline by approximately 2.5% to 4% on a currency-neutral basis.</li> <li>The<span> company estimates a non-GAAP operating margin of between 12.75% to 13.25%, which now also includes the impact of a one-time acquired in-process research and development expense related to an acquisition completed during the third quarter.</span> </li> </ul> </body></html>","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-Rad Labs misses Q3 estimates for profit, revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-Rad Labs misses Q3 estimates for profit, revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-01 14:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4232618-bio-rad-labs-misses-q3-estimates-for-profit-revenue><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bio-Rad Labs press release  (NYSE:BIO): Q3 Non-GAAP EPS of $2.01  misses by $0.87. Revenue of $649.7M (+2.8% Y/Y)  misses by $32.45M. Bio-Rad continues to expect its non-GAAP revenue to decline by ...</p>\n\n<a href=\"https://seekingalpha.com/news/4232618-bio-rad-labs-misses-q3-estimates-for-profit-revenue\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIO","symbol_name":"Bio Rad实验室","start_time":0,"source_url":"https://seekingalpha.com/news/4232618-bio-rad-labs-misses-q3-estimates-for-profit-revenue","article_id":"2480079950","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480079950","pubTimestamp":1730443180,"columns":[],"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"Bio-Rad Labs press release  : Q3 Non-GAAP EPS of $2.01  misses by $0.87. Revenue of $649.7M   misses by $32.45M. Bio-Rad continues to expect its non-GAAP revenue to decline by approximately 2.5% to 4% on a currency-neutral basis. The company estimates a non-GAAP operating margin of between 12.75% to 13.25%, which now also includes the impact of a one-time acquired in-process research and development expense related to an acquisition completed during the third quarter.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BIO":"Bio Rad实验室"},"translate_title":"Bio-Rad Labs第三季度利润和收入未达到预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIO":0.9},"content_text":"Bio-Rad Labs press release  (NYSE:BIO): Q3 Non-GAAP EPS of $2.01  misses by $0.87. Revenue of $649.7M (+2.8% Y/Y)  misses by $32.45M. Bio-Rad continues to expect its non-GAAP revenue to decline by approximately 2.5% to 4% on a currency-neutral basis. The company estimates a non-GAAP operating margin of between 12.75% to 13.25%, which now also includes the impact of a one-time acquired in-process research and development expense related to an acquisition completed during the third quarter.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}